Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 32

Results For "license"

417 News Found

Bristol Myers Squibb’s application for Opdivo plus chemotherapy receives USFDA priority review
Biotech | March 01, 2022

Bristol Myers Squibb’s application for Opdivo plus chemotherapy receives USFDA priority review

If approved, Opdivo plus chemotherapy would be the first neoadjuvant immunotherapy-based option for patients with resectable non-small cell lung cancer in the U.S.


Biocon Biologics acquires Viatris’ biosimilar assets for up to US $ 3.3 billion
News | February 28, 2022

Biocon Biologics acquires Viatris’ biosimilar assets for up to US $ 3.3 billion

BBL will gain Viatris’ global biosimilars business whose revenues are estimated to be USD 1 billion next year, along with its portfolio of in-licensed biosimilar assets


Cantex and Harvard's Wyss Institute to expand development of Azeliragon
News | February 27, 2022

Cantex and Harvard's Wyss Institute to expand development of Azeliragon

Cantex also plans to initiate Phase 2 clinical trials exploring the therapeutic effect of azeliragon in pancreatic and breast cancers.


Mandaviya launches ICMR/ DHR policy on biomedical innovation & entrepreneurship
Policy | February 25, 2022

Mandaviya launches ICMR/ DHR policy on biomedical innovation & entrepreneurship

This policy will ensure multi-disciplinary collaboration, promote start-up culture and develop an innovation-led ecosystem at medical institutes across the country


Daewoong Pharmaceutical posts strong financials in 2021
News | February 22, 2022

Daewoong Pharmaceutical posts strong financials in 2021

Daewoong delivered KRW 1.055 trillion in sales, KRW 95.5 billion in operating profit and KRW 40.5 billion in net profit.


USFDA accepts for Priority Review Bristol Myers Squibb’s Supplemental BLA for Breyanzi
Biotech | February 17, 2022

USFDA accepts for Priority Review Bristol Myers Squibb’s Supplemental BLA for Breyanzi

Application based on the pivotal Phase 3 TRANSFORM study in which Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years


Lupin signs distribution agreement with Medis for Orphan Drug NaMuscla@
News | February 09, 2022

Lupin signs distribution agreement with Medis for Orphan Drug NaMuscla@

NDM disorders are a group of rare, inherited neuromuscular disorders which is characterized by the inability to relax muscles following voluntary contraction


Everest Medicines' trodelvy approved in Singapore for second-line metastatic triple-negative breast cancer
Drug Approval | February 08, 2022

Everest Medicines' trodelvy approved in Singapore for second-line metastatic triple-negative breast cancer

Singapore Health Sciences Authority (HSA) approval marks the first in a series of expected approvals of trodelvy in Asia


AsterDM Healthcare Q3FY22 PAT at Rs 148.34 cr.
News | February 08, 2022

AsterDM Healthcare Q3FY22 PAT at Rs 148.34 cr.

Aster DM Healthcare has reported consolidated financial results for the period ended December 31, 2021


Dr. Reddy's set to acquire Nimbus Health
News | February 03, 2022

Dr. Reddy's set to acquire Nimbus Health

The acquisition will allow Dr. Reddy's to build on Nimbus Health's strengths and introduce medical cannabis-based medicines as a promising treatment option for patients